Synergistic Effects of IGF-1 and Myostatin Modulation in Muscle
Pediatric and adult muscular dystrophies share a common
characteristic of progressive weakness and wasting. Therapies aiming
to increase muscle growth would not cure the underlying
pathophysiology of these disorders but potentially improve function.
IGF-1 is a potent inducer of muscle growth and myostatin is a
specific inhibitor of muscle growth. Stimulating IGF-1 and
inhibiting myostatin pathways induces muscle growth and regeneration
and improves several features of the mdx mouse model of muscular
dystrophy. The goal of this revised project is to evaluate the
potential synergistic actions of these modulators of muscle growth
and to evaluate the potential convergence of these signaling
pathways. The specific aims are: 1) To determine if there are
additive effects on muscle growth in mice genetically lacking
myostatin and also constitutively overexpressing IGF-1. 2) To
determine if the mdx mouse has a milder muscular dystrophy in the
absence of myostatin and the constitutive overexpression of IGF-1
than with either modification alone. 3) To determine if postnatal
IGF-1 stimulation and postnatal myostatin inhibition have additive
effects in normal and utr/mdx mice and 4) To evaluate the potential
convergence of IGF-1 and myostatin signaling pathways through Akt.
The results from these experiments will provide important
preclinical data on whether these strategies of enhancing muscle
growth and regeneration can be successfully used in combination for
the treatment of muscular dystrophies.
Lay summary: Muscle size and strength are influenced by growth
factors including myostatin which inhibits muscle growth and IGF-1
which stimulated muscle growth. Recently, clinical trials began in
muscular dystrophy patients with study drugs that affect the action
of these growth factors. This project will provide preclinical data
on the potential benefits or toxicity of regulating both myostatin
and IGF-1 simultaneously.